Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$50.97
-1.9%
$42.24
$23.62
▼
$59.97
$32.43B0.736.43 million shs2.96 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$119.80
-1.7%
$110.51
$90.39
▼
$212.75
$26.73B0.833.74 million shs1.94 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.73
+0.1%
$37.26
$19.96
▼
$42.50
$28.05B1.238.97 million shs3.72 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-1.91%-5.38%+32.39%+52.56%+68.11%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
-1.69%-0.79%+25.72%-4.22%-40.58%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.05%-7.46%+11.61%+5.13%+88.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$50.97
-1.9%
$42.24
$23.62
▼
$59.97
$32.43B0.736.43 million shs2.96 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$119.80
-1.7%
$110.51
$90.39
▼
$212.75
$26.73B0.833.74 million shs1.94 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.73
+0.1%
$37.26
$19.96
▼
$42.50
$28.05B1.238.97 million shs3.72 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-1.91%-5.38%+32.39%+52.56%+68.11%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
-1.69%-0.79%+25.72%-4.22%-40.58%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.05%-7.46%+11.61%+5.13%+88.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.00
Buy$53.504.96% Upside
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
2.92
Moderate Buy$196.5264.04% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8220.88% Upside

Current Analyst Ratings Breakdown

Latest IMGN, GMAB, ROIV, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D-)
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/13/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Lower Price TargetEqual Weight$57.00 ➝ $56.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
UpgradeHold (C+) ➝ Buy (B-)
11/4/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageBuy$220.00
11/2/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy
11/2/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetBuy$205.00 ➝ $201.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Boost Price TargetEqual Weight$42.00 ➝ $57.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Boost Price TargetBuy$58.00 ➝ $80.00
10/29/2026
Insmed, Inc. stock logo
INSM
Insmed
Set Price Target$195.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$4.30B7.40$1.58 per share32.28$10.15 per share5.02
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
Insmed, Inc. stock logo
INSM
Insmed
$606.42M43.34N/AN/A$3.31 per share36.19
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,397.36N/AN/A$6.34 per share6.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.1743.5632.062.0916.97%13.67%6.42%N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$2.82N/A193.23N/A-39.85%-96.38%-32.55%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%2/5/2027 (Estimated)

Latest IMGN, GMAB, ROIV, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36$0.56+$0.20$0.5510$1.20 billion$1.19 billion
10/29/2026Q3 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.3827-$0.46-$0.0773-$0.46$500.36 million$524.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.74
2.45
2.43
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
Insmed, Inc. stock logo
INSM
Insmed
0.77
2.86
2.59
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664219.38 million214.77 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721724.56 million660.80 millionOptionable

Recent News About These Companies

Roivant Sciences Ltd
Roivant Sciences Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$50.97 -0.99 (-1.91%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$51.62 +0.66 (+1.29%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Insmed stock logo

Insmed NASDAQ:INSM

$119.80 -2.06 (-1.69%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$121.50 +1.70 (+1.41%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.73 +0.02 (+0.05%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$38.75 +0.02 (+0.04%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.